Tagraxofusp plus venetoclax for newly diagnosed BPDCN
Treatments studied
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of BPDCN and have not received any treatment for it yet.
- You are 18 years or older.
- Your kidneys, heart, and liver work well enough based on standard blood and heart tests.
- You are able to get around and take care of yourself (ECOG score 0-2).
- You are not pregnant or breastfeeding, and you agree to use highly effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with a rare blood cancer called BPDCN who are starting or recently started a medicine called Elzonris (tagraxofusp). It collects health information to see how the treatment works over time.
This Phase 2 trial tests venetoclax combined with chemotherapy to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). It may help shrink BPDCN and control the disease, whether you’re newly diagnosed or the cancer has come back.
This trial tests a drug called tagraxofusp combined with a gentle chemotherapy regimen for people whose acute myeloid leukemia (AML) has come back or not responded to an initial venetoclax-based treatment. The study focuses on patients whose leukemia cells have a protein called CD123 on their surface.
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
Hear when a new Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.